The results demonstrate that high FDX1 expression is strongly positively associated with the upgraded drug sensitivity of several human cell lines to chemotherapeutic drugs, expect for everolimus and ammonified with increased drug resistance (Figure 8C), such as resistance to ifosfamide (treatment for recurrent testicular cancer and germ cell tumors, sarcomas, non-Hodgkin’s lymphoma, Hodgkin’s disease, non-small-cell and small-cell lung cancer and bladder cancer, head and neck cancer, and cervical cancer). This evidence concerns the gene FDX1 and urinary bladder carcinoma.